Hong Kong Stock Movement: AB&B BIO-TECH-B signs a strategic cooperation agreement but falls 18.22%, market doubts the effectiveness of the cooperation

Hong Kong Stock Movement AB&B BIO-TECH-B fell 18.22%. Based on recent key news: On March 13, AB&B BIO-TECH-B signed a strategic cooperation agreement with Watson Bio (Hong Kong) Limited to expand the overseas market for subunit influenza vaccines. This move aims to accelerate product promotion in markets such as Southeast Asia and Latin America through Watson Bio's channel advantages; however, the stock price has seen a significant decline, possibly reflecting market concerns about the effectiveness of the cooperation. Source: Jinshi Data On March 13, Watson Bio announced a strategic cooperation with AB&B BIO-TECH for overseas markets, with both parties expected to collaborate deeply, anticipating performance growth in the coming years. However, the market remains cautious about the actual impact of the cooperation, leading to a drop in stock price. Source: People's Finance News On March 16, AB&B BIO-TECH reached a vaccine cooperation agreement with Watson Hong Kong, with the stock price dropping 13%. The market's reaction to the cooperation agreement was less than expected, potentially affecting investor confidence. Source: Huigang Communications. The vaccine industry is facing intensified competition, with high market volatility risks. Stocks with High Trading Volume in the Industry Kangfang Biotech rose 5.26%. Based on recent key news: On March 16, Kangfang Biotech announced that its trispecific antibody AK150 received clinical trial approval from the National Medical Products Administration. This news drove the stock price up by 5.26%. Source: PR Newswire On March 16, AK150 achieved multi-pathway immune suppression relief by blocking CSF1R/ILT2/ILT4, enhancing anti-tumor immune response. This technological breakthrough boosted market confidence. Source: PR Newswire On March 16, AK150 demonstrated a dose-dependent tumor suppression effect in animal models, further supporting its clinical potential. Source: PR Newswire. The biopharmaceutical industry's innovation drives stock price fluctuations. Innovent Biologics rose 3.77%. Based on recent key news: On March 13, Innovent Biologics' Tislelizumab and Icotinib saw revenue growth in the domestic market, with a decrease in sales expense ratio, boosting the company's profitability. This indicates that the sustained volume of products in the market provides profit opportunities for the company. Source: Zhito Finance On March 13, traditional domestic pharmaceutical companies have increased their reserves of innovative drugs, intensifying competition. Innovent Biologics achieved profitability in this context, demonstrating its competitive advantage in the market. Source: Zhito Finance On March 13, Biotech companies face competitive pressure from traditional pharmaceutical companies. Innovent Biologics realized phased value through BD transactions and listings, enhancing market confidence. Source: Zhito Finance. The biopharmaceutical industry is experiencing intensified competition, with increased reserves of innovative drugs. BeiGene rose 2.05%. Based on recent news: On March 13, BeiGene's Tislelizumab and Icotinib maintained revenue growth in the domestic market, with a decrease in sales expense ratio, boosting the company's profitability. This indicates that the company's products continue to gain market share, and despite being in a loss-making phase, the company still has opportunities to weather the toughest times On March 15, data from the Shanghai Stock Exchange showed that enterprises in the Sci-Tech Innovation Growth sector overall exhibited a trend of "increased revenue and reduced losses," with 39 companies experiencing a year-on-year revenue growth of 37% for the fiscal year 2025 and a year-on-year reduction in net losses of 57%. This trend indicates an increased market support for technology innovation companies, benefiting firms like BeiGene. On March 13, traditional pharmaceutical companies, after several years of transformation and layout, have developed a relatively rich pipeline of self-researched products, and their reserves of innovative drugs are not significantly inferior to those of Biotech firms. As a Biotech company, BeiGene faces increased competitive pressure from traditional pharmaceutical companies, but the market performance of its core products remains strong. Overall, Sci-Tech Innovation Board companies are experiencing increased revenue and reduced losses, with heightened market support. Stocks Ranked Among the Top by Market Capitalization in the Industry Kelong Botai Biotechnology-B, up 4.81%, with a market capitalization reaching HKD 96.5 billion, has had no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation